valproic acid has been researched along with Hypertrophy in 5 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Hypertrophy: General increase in bulk of a part or organ due to CELL ENLARGEMENT and accumulation of FLUIDS AND SECRETIONS, not due to tumor formation, nor to an increase in the number of cells (HYPERPLASIA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Angiotensin II (Ang II) plays a pathophysiological role in the genesis of cardiac hypertrophy as a hypertrophic stimulus." | 7.75 | Angiotensin II induces cardiomyocyte hypertrophy probably through histone deacetylases. ( Lu, Y; Yang, S, 2009) |
| "Pregnancy was otherwise uneventful." | 5.32 | Multiple congenital malformations including generalized hypertrichosis with gum hypertrophy in a child exposed to valproic acid in utero. ( Audeoud, F; Bernardin, A; Gaugler, C; Messer, J; Stoll, C, 2003) |
| " Valproic acid (VPA) was found to enhance alpha7 integrin levels, induce muscle hypertrophy, and inhibit apoptosis in myotubes by activating the Akt/mTOR/p70S6K pathway." | 3.75 | Valproic acid activates the PI3K/Akt/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy. ( Burkin, DJ; Gurpur, PB; Kaufman, SJ; Liu, J, 2009) |
| "Angiotensin II (Ang II) plays a pathophysiological role in the genesis of cardiac hypertrophy as a hypertrophic stimulus." | 3.75 | Angiotensin II induces cardiomyocyte hypertrophy probably through histone deacetylases. ( Lu, Y; Yang, S, 2009) |
| "Pregnancy was otherwise uneventful." | 1.32 | Multiple congenital malformations including generalized hypertrichosis with gum hypertrophy in a child exposed to valproic acid in utero. ( Audeoud, F; Bernardin, A; Gaugler, C; Messer, J; Stoll, C, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Manivasagam, S | 1 |
| Velusamy, T | 1 |
| Sowndharajan, B | 1 |
| Chandrasekar, N | 1 |
| Dhanusu, S | 1 |
| Vellaichamy, E | 1 |
| Gurpur, PB | 1 |
| Liu, J | 1 |
| Burkin, DJ | 1 |
| Kaufman, SJ | 1 |
| Lu, Y | 1 |
| Yang, S | 1 |
| Stoll, C | 1 |
| Audeoud, F | 1 |
| Gaugler, C | 1 |
| Bernardin, A | 1 |
| Messer, J | 1 |
| Gulati, S | 1 |
| Thukral, A | 1 |
5 other studies available for valproic acid and Hypertrophy
| Article | Year |
|---|---|
Valporic acid enhances the Atrial Natriuretic Peptide (ANP) mediated anti-hypertrophic activity by modulating the Npr1 gene transcription in H9c2 cells in vitro.
Topics: Animals; Atrial Natriuretic Factor; Biomarkers; Cell Line; Cyclic GMP; Drug Synergism; Gene Expressi | 2017 |
Valproic acid activates the PI3K/Akt/mTOR pathway in muscle and ameliorates pathology in a mouse model of Duchenne muscular dystrophy.
Topics: Animals; beta-Galactosidase; Carrier Proteins; Cell Culture Techniques; Disease Models, Animal; Enzy | 2009 |
Angiotensin II induces cardiomyocyte hypertrophy probably through histone deacetylases.
Topics: Angiotensin II; Animals; Animals, Newborn; Cell Enlargement; Cell Size; Cells, Cultured; Gene Expres | 2009 |
Multiple congenital malformations including generalized hypertrichosis with gum hypertrophy in a child exposed to valproic acid in utero.
Topics: Abnormalities, Multiple; Anticonvulsants; Dermatoglyphics; Epilepsy; Fatal Outcome; Female; Gingiva; | 2003 |
Valproate and gum hypertrophy.
Topics: Anticonvulsants; Child; Female; Gingiva; Humans; Hypertrophy; Valproic Acid | 2004 |